QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (88) Citing Articles via Google Scholar Google Scholar Articles by Vila, M. Articles by Hirsch, E. C. Search for Related Content PubMed PubMed Citation Articles by Vila, M. Articles by Hirsch, E. C.

 Previous Article  |  Next Article 

Volume 17, Number 2, Issue of January 15, 1997 pp. 765-773
Copyright ©1997 Society for Neuroscience

Consequences of Nigrostriatal Denervation on the Functioning of the Basal Ganglia in Human and Nonhuman Primates: An In Situ Hybridization Study of Cytochrome Oxidase Subunit I mRNA

Received Aug. 5, 1996; revised Oct. 28, 1996; accepted Oct. 29, 1996.

Miquel Vila¹, Richard Levy¹, Maria-Trinidad Herrero², Merle Ruberg¹, Baptiste Faucheux¹, José A. Obeso³, Yves Agid¹, and Etienne C. Hirsch¹

¹ Institut National de la Santé et de la Recherche Médicale U289, Hôpital de la Salpêtrière, 75013 Paris, France, ² Department of Anatomy, University of Murcia, 30071 Murcia, Spain, and ³ Department of Neurology and Functional Neurosurgery, Quiron Clinic, 20012 San Sebastian, Spain

To examine the consequences of nigrostriatal denervation and chronic levodopa (L-DOPA) treatment on functional activity of the basal ganglia, we analyzed, using in situ hybridization, the cellular expression of the mRNA encoding for cytochrome oxidase subunit I (COI mRNA), a molecular marker for functional neuronal activity, in the basal ganglia. This analysis was performed in monkeys rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication, some of which had been receiving L-DOPA, and in patients with Parkinson's disease (PD). In MPTP-intoxicated monkeys compared with control animals, COI mRNA expression was increased in the subthalamic nucleus (STN) and in the output nuclei of the basal ganglia, i.e., the internal segment of the globus pallidus and the substantia nigra pars reticulata. This increase was partially reversed by L-DOPA treatment. COI mRNA expression remained unchanged in the external segment of the globus pallidus (GPe). In PD patients, all of whom had been treated chronically by L-DOPA, COI mRNA expression in the analyzed basal ganglia structures was similar to that in control subjects. These results are in agreement with the accepted model of basal ganglia organization, to the extent that the output nuclei of the basal ganglia are considered to be overactive after nigrostriatal denervation, partly because of increased activity of excitatory afferents from the STN. Yet, our results would also seem to contradict this model, because the overactivity of the STN does not seem to be attributable to a hypoactivation of the GPe.

Key words: Parkinson's disease; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; L-DOPA; cytochrome oxidase; in situ hybridization; basal ganglia

This article has been cited by other articles:

				K. Mukhida, M. Hong, G.B. Miles, T. Phillips, B.A. Baghbaderani, M. McLeod, N. Kobayashi, A. Sen, L.A. Behie, R.M. Brownstone, et al. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats Brain, August 1, 2008; 131(8): 2106 - 2126. [Abstract] [Full Text] [PDF]

				A.-S. Rolland, M.-T. Herrero, V. Garcia-Martinez, M. Ruberg, E. C. Hirsch, and C. Francois Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism Brain, January 1, 2007; 130(1): 265 - 275. [Abstract] [Full Text] [PDF]

				M. C. Rodriguez-Oroz, J. A. Obeso, A. E. Lang, J.-L. Houeto, P. Pollak, S. Rehncrona, J. Kulisevsky, A. Albanese, J. Volkmann, M. I. Hariz, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up Brain, October 1, 2005; 128(10): 2240 - 2249. [Abstract] [Full Text] [PDF]

				W. -L. Kuan and R. A. Barker New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants Neurorehabil Neural Repair, September 1, 2005; 19(3): 155 - 181. [Abstract] [PDF]

				J. Soares, M. A. Kliem, R. Betarbet, J. T. Greenamyre, B. Yamamoto, and T. Wichmann Role of External Pallidal Segment in Primate Parkinsonism: Comparison of the Effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism and Lesions of the External Pallidal Segment J. Neurosci., July 21, 2004; 24(29): 6417 - 6426. [Abstract] [Full Text] [PDF]

				J. A. Obeso, M. Rodriguez-Oroz, C. Marin, F. Alonso, I. Zamarbide, J. L. Lanciego, and M. Rodriguez-Diaz The origin of motor fluctuations in Parkinson's disease: Importance of dopaminergic innervation and basal ganglia circuits Neurology, January 13, 2004; 62(90011): S17 - 30. [Abstract] [Full Text]

				N. Breysse, M. Amalric, and P. Salin Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats J. Neurosci., September 10, 2003; 23(23): 8302 - 8309. [Abstract] [Full Text] [PDF]

				G. Orieux, C. Francois, J. Feger, and E. C. Hirsch Consequences of Dopaminergic Denervation on the Metabolic Activity of the Cortical Neurons Projecting to the Subthalamic Nucleus in the Rat J. Neurosci., October 1, 2002; 22(19): 8762 - 8770. [Abstract] [Full Text] [PDF]

				G. Heimer, I. Bar-Gad, J. A. Goldberg, and H. Bergman Dopamine Replacement Therapy Reverses Abnormal Synchronization of Pallidal Neurons in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Primate Model of Parkinsonism J. Neurosci., September 15, 2002; 22(18): 7850 - 7855. [Abstract] [Full Text] [PDF]

				N. Breysse, C. Baunez, W. Spooren, F. Gasparini, and M. Amalric Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism J. Neurosci., July 1, 2002; 22(13): 5669 - 5678. [Abstract] [Full Text] [PDF]

				M. C. Rodriguez-Oroz, M. Rodriguez, J. Guridi, K. Mewes, V. Chockkman, J. Vitek, M. R. DeLong, and J. A. Obeso The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics Brain, September 1, 2001; 124(9): 1777 - 1790. [Abstract] [Full Text] [PDF]

				D. E. Chapman, G. R. Hanson, R. P. Kesner, and K. A. Keefe Long-Term Changes in Basal Ganglia Function after a Neurotoxic Regimen of Methamphetamine J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 520 - 527. [Abstract] [Full Text]

				C. Beurrier, P. Congar, B. Bioulac, and C. Hammond Subthalamic Nucleus Neurons Switch from Single-Spike Activity to Burst-Firing Mode J. Neurosci., January 15, 1999; 19(2): 599 - 609. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help